Denosumab
Xgeva · Anti-RANKL antibody
Severe hypocalcemia in low GFR; not directly nephrotoxic.
Itovebi · PI3Kalpha inhibitor
PI3Kα inhibitor · approved 2024 · 4 citations · FAERS AKI reporting ROR 3.03 (95% CI 1.96–4.68, 21 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
PI3Kalpha inhibitor whose renal-relevant toxicity is metabolic, hyperglycemia and electrolyte shifts, not a defined kidney lesion
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity from inavolisib is not prominent and renal-specific data are limited; the headline metabolic toxicity is on-target hyperglycemia. In the INAVO120 phase 3 trial, grade 3 or 4 hyperglycemia occurred in 5.6 percent of the inavolisib group versus 0 percent with placebo, alongside higher rates of stomatitis and diarrhea (which can secondarily cause volume and electrolyte loss). A defined inavolisib-specific kidney lesion with an established electrolyte-event incidence rate is not characterized, so no headline signature rate is charted (the 5.6% grade 3/4 hyperglycemia figure is a metabolic, not electrolyte, signal).Source: 39476340
On-target hyperglycemia appears soon after dosing, sometimes peaking within hours of ingestion, and reverses within days of holding.
Distilled from: “Hyperglycemia from PI3Kalpha inhibition is an on-target effect that can appear soon after dosing, sometimes with peak glucose elevations in the hours following ingestion, and typically reverses within days of holding the drug.”
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Inavolisib is a highly potent, selective small-molecule inhibitor of the p110alpha catalytic subunit of PI3K (encoded by PIK3CA) that also promotes degradation of mutant p110alpha. By blocking and depleting oncogenic PI3Kalpha signaling it suppresses the PI3K/AKT/mTOR pathway that drives PIK3CA-mutated, HR-positive/HER2-negative breast cancer. It is used in combination with palbociclib and fulvestrant to overcome endocrine resistance.
Distal Tubule / Collecting Duct
Fine-tuning of Na, K, Mg, acid & water
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Apr 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Reduce the dosage in patients with moderate (eGFR 30 to < 60 mL/min) and severe (eGFR < 30 mL/min) renal impairment [see Dosage and Administration (2.5) ] . No dosage modification is recommended in patients with mild renal impairment (eGFR 60 to < 90 mL/min).
Kidney rows of the label's dosage tables
From the Itovebi label (Apr 2026) · DailyMed
No row of this label's 2 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 670 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
32 of 670 reports
Reported with hospitalization
221 of 670 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Inavolisib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Xgeva · Anti-RANKL antibody
Severe hypocalcemia in low GFR; not directly nephrotoxic.
Portrazza · Anti-EGFR antibody
Severe hypomagnesemia, class effect.
Rybrevant · EGFR-MET bispecific antibody
EGFR-mediated electrolyte (magnesium) wasting; an emerging acute interstitial nephritis signal is also clinician-flagged.
Balversa · FGFR inhibitor
Hyperphosphatemia is an on-target class effect.
Lytgobi · FGFR inhibitor
Hyperphosphatemia, class effect.
Pemazyre · FGFR inhibitor
Hyperphosphatemia; nephrocalcinosis risk.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.